Search Results - "Leffers, Ninke"

HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+T lymphocytes by Gooden, Marloes, Lampen, Margit, Jordanova, Ekaterina S., Leffers, Ninke, Trimbos, J. Baptist, van der Burg, Sjoerd H., Nijman, Hans, van Hall, Thorbald

“…HLA-E is a nonclassical HLA class I molecule, which differs from classical HLA molecules by its nonpolymorphic, conserved nature. Expression and function of…”
Get full text

Antigen-specific active immunotherapy for ovarian cancer by Paijens, Sterre T, Leffers, Ninke, Daemen, Toos, Helfrich, Wijnand, Boezen, H Marike, Cohlen, Ben J, Melief, Cornelis Jm, de Bruyn, Marco, Nijman, Hans W

“…This is the second update of the review first published in the Cochrane Library (2010, Issue 2) and later updated (2014, Issue 9).Despite advances in…”
Get more information

Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: A single-arm phase II study by Vermeij, Renee, Leffers, Ninke, Hoogeboom, Baukje-Nynke, Hamming, Ineke L.E., Wolf, Rinze, Reyners, Anna K.L., Molmans, Barbara H.W., Hollema, Harry, Bart, Joost, Drijfhout, Jan W., Oostendorp, Jaap, van der Zee, Ate G.J., Melief, Cornelis J., van der Burg, Sjoerd H., Daemen, Toos, Nijman, Hans W.

“…The purpose of the current phase II single‐arm clinical trial was to evaluate whether pretreatment with low‐dose cyclophosphamide improves immunogenicity of a…”
Get full text

Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcome by Brunekreeft, Kim L., Paijens, Sterre T., Wouters, Maartje C.A., Komdeur, Fenne L., Eggink, Florine A., Lubbers, Joyce M., Workel, Hagma H., Van Der Slikke, Elisabeth C., Pröpper, Noor E.J., Leffers, Ninke, Adam, Julien, Pijper, Harry, Plat, Annechien, Kol, Arjan, Nijman, Hans W., De Bruyn, Marco

“…Epithelial Ovarian cancer (EOC) is the most lethal gynecological malignancy and has limited curative therapeutic options. Immunotherapy for EOC is promising,…”
Get full text

The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer by Bijen, Claudia B.M., Bantema‐Joppe, Enja J., de Jong, Renske A., Leffers, Ninke, Mourits, Marian J.E., Eggink, Henk F., van der Zee, Ate G.J., Hollema, Harry, de Bock, Geertruida H., Nijman, Hans W.

“…The aim of this study was to investigate classical MHC class I and nonclassical MHC (human leukocyte antigen‐G [HLA‐G]) expression in a large cohort of…”
Get full text

Serum Cytokine Profiling as a Diagnostic and Prognostic Tool in Ovarian Cancer: A Potential Role for Interleukin 7 by LAMBECK, Annechien J. A, CRIJNS, Anne P. G, LEFFERS, Ninke, SLUITER, Wim J, TEN HOOR, Klaske A, BRAID, Mike, VAN DER ZEE, Ate G. J, DAEMEN, Toos, NIJMAN, Hans W, KAST, W. Martin

“…Purpose: To evaluate if serum cytokine levels could be used as diagnostic or prognostic markers in ovarian cancer. Experimental Design: A cytokine bead array…”
Get full text

Antigen-specific active immunotherapy for ovarian cancer by Leffers, Ninke, Daemen, Toos, Helfrich, Wijnand, Boezen, H Marike, Cohlen, Ben J, Melief, Kees, Nijman, Hans W

“…Despite advances in chemotherapy, prognosis of ovarian cancer remains poor. Antigen-specific active immunotherapy aims to induce a tumour-antigen-specific…”
Get more information

Antigen-specific immunotherapy in ovarian cancer and p53 as tumor antigen by Vermeij, Renee, Leffers, Ninke, Melief, Cornelis J, Daemen, Toos, Nijman, Hans W

“…Immunotherapy for ovarian cancer is one of the new treatment strategies currently investigated in epithelial ovarian cancer. This review discusses the results…”
Get more information

Potential Target Antigens for a Universal Vaccine in Epithelial Ovarian Cancer by Vermeij, Renee, Daemen, Toos, de Bock, Geertruida H., de Graeff, Pauline, Leffers, Ninke, Lambeck, Annechien, ten Hoor, Klaske A., Hollema, Harry, van der Zee, Ate G. J., Nijman, Hans Wilhelm

“…The prognosis of epithelial ovarian cancer (EOC), the primary cause of death from gynaecological malignancies, has only modestly improved over the last…”
Get full text

Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer by Leffers, Ninke, Gooden, Marloes J. M, de Jong, Renske A, Hoogeboom, Baukje-Nynke, ten Hoor, Klaske A, Hollema, Harry, Boezen, H. Marieke, van der Zee, Ate G. J, Daemen, Toos, Nijman, Hans W

“…Purpose Ovarian cancer patients with intra-tumoral CD3⁺ T-lymphocytes in primary tumor tissue have a better prognosis. This study aims to analyze the presence…”
Get full text

CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy by Komdeur, Fenne L, Wouters, Maartje C A, Workel, Hagma H, Tijans, Aline M, Terwindt, Anouk L J, Brunekreeft, Kim L, Plat, Annechien, Klip, Harry G, Eggink, Florine A, Leffers, Ninke, Helfrich, Wijnand, Samplonius, Douwe F, Bremer, Edwin, Wisman, G Bea A, Daemen, Toos, Duiker, Evelien W, Hollema, Harry, Nijman, Hans W, de Bruyn, Marco

“…CD103+ tumor-infiltrating lymphocytes (TIL) have been linked to specific epithelial infiltration and a prolonged survival in high-grade serous epithelial…”
Get full text

Abstract 1687: Systemic immunological changes during first line chemotherapy in patients with high-grade serous ovarian cancer by Komdeur, Fenne L., Eggink, Florine A., Leffers, Ninke, Workel, Hagma H., Brunekreeft, Kim L., Plat, Annechien, Bruyn, Marco de, Nijman, Hans W.

“…Abstract Ovarian cancer remains the most lethal gynecological malignancy and new therapeutic strategies are urgently needed. High-grade serous ovarian cancer…”
Get full text

Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial by Leffers, Ninke, Lambeck, Annechien J.A., Gooden, Marloes J.M., Hoogeboom, Baukje‐Nynke, Wolf, Rinze, Hamming, Ineke E., Hepkema, Bouke G., Willemse, Pax H.B., Molmans, Barbara H.W., Hollema, Harry, Drijfhout, Jan W., Sluiter, Willem J., Valentijn, A. Rob P.M., Fathers, Loraine M., Oostendorp, Jaap, van der Zee, Ate G.J., Melief, Cornelis J., van der Burg, Sjoerd H., Daemen, Toos, Nijman, Hans W.

“…The prognosis of ovarian cancer, the primary cause of death from gynecological malignancies, has only modestly improved over the last decades. Immunotherapy is…”
Get full text

Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer by Leffers, Ninke, Vermeij, Renee, Hoogeboom, Baukje-Nynke, Schulze, Ute R., Wolf, Rinze, Hamming, Ineke E., van der Zee, Ate G., Melief, Kees J., van der Burg, Sjoerd H., Daemen, Toos, Nijman, Hans W.

“…Vaccine‐induced p53‐specific immune responses were previously reported to be associated with improved response to secondary chemotherapy in patients with small…”
Get full text

Antigen-specific active immunotherapy for ovarian cancer by Leffers, Ninke, Daemen, Toos, Helfrich, Wijnand, Boezen, H Marike, Cohlen, Ben J, Melief, Cornelis J M, Nijman, Hans W

“…Despite advances in chemotherapy, prognosis of ovarian cancer remains poor. Antigen-specific active immunotherapy aims to induce tumour-antigen-specific…”
Get more information

Immunological and Clinical Effects of Vaccines Targeting p53-Overexpressing Malignancies by Vermeij, Renee, Leffers, Ninke, van der Burg, S. H., Melief, C. J., Daemen, Toos, Nijman, Hans Wilhelm

“…Approximately 50% of human malignancies carry p53 mutations, which makes it a potential antigenic target for cancer immunotherapy. Adoptive transfer with…”
Get full text

HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8⁺ T lymphocytes by Gooden, Marloes, Lampen, Margit, Jordanova, Ekaterina S, Leffers, Ninke, Trimbos, J. Baptist, van der Burg, Sjoerd H, Nijman, Hans, van Hall, Thorbald

“…HLA-E is a nonclassical HLA class I molecule, which differs from classical HLA molecules by its nonpolymorphic, conserved nature. Expression and function of…”
Get full text

Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation by Leffers, Ninke, Lambeck, Annechien J.A, de Graeff, Pauline, Bijlsma, Astrid Y, Daemen, Toos, van der Zee, Ate G.J, Nijman, Hans W

“…Abstract Objectives The adaptive immune system seems to play an essential role in the natural course of ovarian cancer. Aim of this study was to establish…”
Get full text

Tumor-infiltrating Cytotoxic T Lymphocytes as Independent Prognostic Factor in Epithelial Ovarian Cancer With Wilms Tumor Protein 1 Overexpression by VERMEIJ, Renee, DE BOCK, Geertruida H, LEFFERS, Ninke, TEN HOOR, Klaske A, SCHULZE, Ute, HOLLEMA, Harry, VAN DER BURG, Sjoerd H, VAN DER ZEE, Ate G. J, DAEMEN, Toos, NIJMAN, Hans W

“…Immune response characterization at the primary tumor site enables the design of therapeutic vaccination strategies with higher efficacy in epithelial ovarian…”
Get full text

P53‐specific T cell responses in patients with malignant and benign ovarian tumors: Implications for p53 based immunotherapy by Lambeck, Annechien, Leffers, Ninke, Hoogeboom, Baukje‐Nynke, Sluiter, Wim, Hamming, Ineke, Klip, Harry, ten Hoor, Klaske, Esajas, Martha, van Oven, Magda, Drijfhout, Jan‐Wouter, Platteel, Inge, Offringa, Rienk, Hollema, Harry, Melief, Kees, van der Burg, Sjoerd, van der Zee, Ate, Daemen, Toos, Nijman, Hans

“…Despite intensive treatment, 70% of the ovarian cancer patients will develop recurrent disease, emphasizing the need for new approaches such as immunotherapy…”
Get full text